|
1.
|
Cyster JG: Chemokines,
sphingosine-1-phosphate, and cell migration in secondary lymphoid
organs. Ann Rev Immunol. 23:127–159. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
von Andrian U and Mackay CR: T-cell
function and migration: two sides of the same coin. N Engl J Med.
343:1020–1034. 2000.
|
|
3.
|
Campbell JJ and Butcher EC: Chemokines in
tissue-specific and microenvironment-specific lymphocyte homing.
Curr Opin Immunol. 12:336–341. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Okada T, Ngo VN, Ekland EH, et al:
Chemokine requirements for B cell entry into lymph nodes and peyers
patches. J Exp Med. 196:65–75. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Matloubain M, Lo CG, Cinamon G, et al:
Lymphocyte egress from thymus and peripheral lymphoid organs is
dependent on S1P receptor 1. Nature. 427:355–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Lo CG, Xu Y, Proia RL and Cyster JG:
Cyclical modulation of sphingosine-1-phosphate receptor 1 surface
expression during lymphocyte recirculation and relationship to
lymphoid organ transit. J Exp Med. 201:291–301. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Muller G, Hopken UE and Lipp M: The impact
of CCR7 and CXCR5 on lymphoid organ development and systemic
immunity. Immunol Rev. 195:117–135. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Cyster JG, Ansel KM, Reif K, et al:
Follicular stromal cells and lymphocyte homing to follicles.
Immunol Rev. 176:181–193. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Nie Y, Waite J, Brewer F, Sunshine MJ,
Littman DR and Zou YR: The role of CXCR4 in maintaining peripheral
B cell compartments and humoral immunity. J Exp Med. 200:1145–1156.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Glodek AM, Honczarenko M, Le Y, Campbell
JJ and Silberstein LE: Sustained activation of cell adhesion is a
differentially regulated process in B lymphopoiesis. J Exp Med.
197:461–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Harnett MH: B cells spread and gather.
Science. 312:709–710. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Laudanna C, Kim JY, Constantin G and
Butcher EC: Rapid leukocyte activation by chemokines. Immunol Rev.
186:37–46. 2002. View Article : Google Scholar
|
|
13.
|
Ostermann G, Weber K, Zernecke A, Schroder
A and Weber C: JAM-1 is a ligand of the β2 integrin
LFA-1 involved in transendothelial migration of leukocytes. Nat
Immunol. 3:151–158. 2002.
|
|
14.
|
Shulman Z, Shinder V, Klein E, et al:
Lymphocyte crawling and transendothelial migration require
chemokine triggering of high-affinity LFA-1 integrin. Immunity.
30:384–396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Lo CG, Lu TT and Cyster JG:
Integrin-dependence of lymphocyte entry into the white pulp. J Exp
Med. 197:353–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Cinamon G, Matloubain M, Lesneski M, et
al: Sphingosine 1-phosphate receptor promotes B cell localization
in the splenic marginal zone. Nat Immunol. 5:713–720. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Ryan DH, Nuccie BL, Abboud CN and Winslow
JM: Vascular cell adhesion molecule-1 and the integrin VLA-4
mediate adhesion of human B cell precursors to cultured bone marrow
adherent cells. J Clin Invest. 88:995–1004. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Gorfu G, Rivera-Nieves J and Ley K: Role
of β7 integrins in intestinal lymphocyte homing and retention. Curr
Mol Med. 9:836–850. 2009.
|
|
19.
|
Hamann A, Andrew DP, Jablonski-Westrich D,
Holzmann B and Butcher EC: Role of α4-integrins in
lymphocytes homing to mucosal tissues in vivo. J Immunol.
152:3282–3293. 1994.
|
|
20.
|
Rosen H and Goetzl EJ: Sphingosine
1-phosphate and its receptors: an autocrine and paracrine network.
Nat Rev Immunol. 5:560–570. 2005. View
Article : Google Scholar
|
|
21.
|
Donovan EE, Pelanda R and Torres R: S1P3
confers differential S1P-induced migration by autoreactive and
non-autoreactive immature B cells and is required for normal B-cell
development. Eur J Immunol. 40:688–698. 2010. View Article : Google Scholar
|
|
22.
|
Foucar K: B cell chronic lymphocytic and
prolymphocytic leukemia. Williams and Wilkins; Baltimore: 1992
|
|
23.
|
Till KJ, Lin K, Zuzel M and Cawley JC: The
chemokine receptor CCR7 and α4 integrin are important for migration
of chronic lymphocytic leukemia cells into lymph nodes. Blood.
99:2977–2984. 2002.
|
|
24.
|
Shanafelt TD, Bone ND, Geyer SM, et al:
Prognostic importance of CD49d expression in chronic lymphocytic
leukemia. Blood. 108:786a2006.
|
|
25.
|
Gattei V, Bulian P, Del Principe MI, et
al: High CD49d protein expression predict short overall survival
and early progression in chronic lymphocytic leukemia patients.
Leuk Lymph. 48(Suppl 1): S602007.
|
|
26.
|
Burger JA, Burger M and Kipps TJ: Chronic
lymphocytic leukemia B cells express functional CXCR4 chemokine
receptors that mediate spontaneous migration beneath bone marrow
stromal cells. Blood. 94:3658–3667. 1999.
|
|
27.
|
Burger JA and Peled A: CXCR4 antagonists:
targeting the micro-environment in leukemia and other cancers.
Leukemia. 23:43–52. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Calissano C, Damle RJ, Hayes G, et al:
In vivo intra- and interclonal kinetic heterogeneity in
B-cell chronic lymphocytic leukaemia. Blood. 114:4832–4842. 2009.
View Article : Google Scholar
|
|
29.
|
Lopez-Giral S, Quintana NE, Caberixo M, et
al: Chemokine receptors that mediated B cell homing to secondary
lymphoid tissues are highly expressed in B cell chronic lymphocytic
leukemia and non-Hodgkin lymphomas with widespread nodular
dissemination. J Leukoc Biol. 76:462–471. 2004. View Article : Google Scholar
|
|
30.
|
Hoellenriegel J, Meadows SA, Sivina M, et
al: The phosphoinositide 3′ kinase delta inhibitor, CAL-101,
inhibits B-cell receptor signaling and chemokine networks in
chronic lymphocytic leukemia. Blood. 118:3603–3612. 2011.
|
|
31.
|
Kinashi T: Intracellular signaling
controlling integrin activation in lymphocytes. Nat Rev Immunol.
5:546–559. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Sasaki AT, Chun C, Takeda K and Firtel RA:
Localised Ras signaling at the leading edge regulates PI3K, cell
polarity, and directional cell movement. J Cell Biol. 167:505–518.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Friedberg JW, Sharman J, Sweetenham J, et
al: Inhibition of Syk with fostamatinib disodium has significant
clinical activity in non-Hodgkin lymphoma and chronic lymphocytic
leukemia. Blood. 115:2578–2585. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Mocsai A, Ruland J and Tybulewicz VLJ: The
SYK tyrosine kinase: a crucial player in diverse biological
functions. Nat Rev Immunol. 10:387–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
de Rooij MFM, Kuil A, Geest CR, et al: The
clinically active BTK inhibitor PCI-32765 targets B-cell receptor-
and chemokine-controlled adhesion and migration in chronic
lymphocytic leukemia. Blood. 119:2590–2594. 2012.PubMed/NCBI
|
|
36.
|
Burger M, Hartmann T, Fujii N, Kipps TJ
and Burger JA: CXCR4 chemokine receptor antagonists inhibit
activation, migration, and survival of chronic lymphocytic leukemia
cells in response to stromal cell-derived factor 1 (SDF-1/CXCL12).
Blood. 102:15852003.
|
|
37.
|
Zuccchetto A, Viasitti T, Benedetti D, et
al: The CD49d/CD29 complex is physically and functionally
associated with CD38 in B-cell chronic lymphocytic leukemia cells.
Leukemia. 26:1293–1300. 2012.
|
|
38.
|
Mackay CR: Moving targets: cell migration
inhibitors as new anti-inflammatory therapies. Nat Immunol.
9:988–998. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Weisberg E, Azab AK, Manley PW, et al:
Inhibition of CXCR4 in CML cells disrupts their interaction with
the bone marrow microenvironment and sensitizes them to nilotinib.
Leukemia. 26:985–990. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Cawley JC: Hairy cell leukemia and the
microenvironment. Leuk Lymph. 52(Suppl 2): S93–S95. 2011.
View Article : Google Scholar
|
|
41.
|
Cawley JC, Zuzel M and Caligaris-Cappio F:
Biology of the hairy cell. Hairy Cell Leukemia. Tallman M and
Polliack A: Harwood Academic Publishers; Newark: pp. 9–18. 1999
|
|
42.
|
Aziz KA, Till KJ, Zuzel M and Cawley JC:
Involvement of CD44-hyaluronan interaction in malignant cell homing
and fibronectin synthesis in hairy cell leukemia. Blood.
96:3161–3167. 2000.PubMed/NCBI
|
|
43.
|
Basso K, Liso A, Tiacci E, et al: Gene
expression profiling of hairy cell leukemia reveals a phenotype
related to memory B cells with altered expression of chemokine and
adhesion receptors. J Exp Med. 199:59–68. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Potsch C, Vohringer D and Pircher H:
Distinct migration patterns of naive and effector CD8 T cells in
the spleen: correlation with CCR7 receptor expression and chemokine
reactivity. Eur J Immunol. 29:3652–3570. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Burger JA, Sivina M and Ravandi F: The
microenvironment in hairy cell leukemia: pathways and potential
therapeutic targets. Leuk Lymph. 52(Suppl 2): S94–S98. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Burthem J, Vincent A and Cawley JC:
Integrin receptors and hairy cell leukaemia. Leuk Lymph.
21:211–215. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Venkataraman G, Aguhar C, Kreitman RJ,
Yuan CM and Stetler-Stevenson M: Characteristic CD103 and CD123
expression pattern defines hairy cell leukemia: usefulness of CD123
and CD103 in the diagnosis of mature B-cell lymphoproliferative
disorders. Am J Clin Pathol. 136:625–630. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Pals ST, de Gorter DJ and Spaargaren M:
Lymphoma dissemination: the other face of lymphocyte homing. Blood.
110:3102–3111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Terol M-J, Lopez-Giuillermo A, Bosch F, et
al: Expression of beta-integrin adhesion molecules in non-Hodgkin’s
lymphoma: correlation with clinical and evolutive features. J Clin
Oncol. 17:1869–1875. 1999.PubMed/NCBI
|
|
50.
|
Janke K, Coupland S, Na I-K, et al:
Expression of the chemokine receptors CXCR4, CXCR5 and CCR7 in
primary central nervous system lymphoma. Blood. 106:384–385. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Cattoretti G, Mandelbaum J, Lee N, et al:
Targeted disruption of the S1P2 sphingosine
1-phosphate receptor gene leads to diffuse large B-cell lymphoma
formation. Cancer Res. 69:8686–8692. 2009.PubMed/NCBI
|
|
52.
|
Lepley D, Paik J-H, Hla T and Ferrer F:
The G protein-coupled receptor S1P2 regulates Rho/Rho
kinase pathway to inhibit tumor cell migration. Cancer Res.
65:3788–3795. 2005.PubMed/NCBI
|
|
53.
|
Klapper W: Pathobiology and diagnosis of
follicular lymphoma. Semin Diagn Pathol. 28:146–160. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Hopken UE, Foss HD, Meyer D, et al:
Up-regulation of the chemokine receptor CCR7 in classical but not
in lymphocyte-predominant Hodgkin disease correlates with distinct
dissemination of neoplastic cells in lymphoid organs. Blood.
99:1109–1116. 2002. View Article : Google Scholar
|
|
55.
|
Coupland SE: The challenge of the
microenvironmnent in B-cell lymphomas. Histopathology. 58:69–80.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Wartenberg M, Vasil P, Meyer C, et al:
Somatic hypermutation analysis in follicular lymphoma provides
evidence suggesting bidirectional cell migration between lymph node
and bone marrow during disease progression and relapse.
Haematologica. 98:1433–1441. 2013. View Article : Google Scholar
|
|
57.
|
Gisbert J and Calvet X: Review article:
common misconceptions in the management of Helicobacter
pylori-associated gastric MALT-lymphoma. Aliment Pharmacol
Ther. 34:1047–1062. 2011.PubMed/NCBI
|
|
58.
|
Piris MA, Arribas A and Mollejo M:
Marginal zone lymphoma. Semin Diagn Pathol. 28:135–145. 2011.
View Article : Google Scholar
|
|
59.
|
Drillenburg P, van der Voort R, Koopman G,
et al: Preferential expression of the mucosal homing receptor
integrin α4β7 in gastrointestinal non-Hodgkin’s lymphomas. Am J
Pathol. 150:919–927. 1997.
|
|
60.
|
Liu YX, Yoshino T, Ohara N, et al: Loss of
expression of α4β7 integrin and L-selectin is associated with
high-grade progression of low-grade MALT lymphoma. Mod Pathol.
14:798–805. 2001.
|
|
61.
|
Trentin L, Cabrelle A, Facco M, et al:
Homeostatic chemokines drive migration of malignant B cells in
patients with non-Hodgkin lymphomas. Blood. 104:502–508. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Sander B: Mantle cell lymphoma: recent
insights into pathogenesis, clinical variability, and new
diagnostic markers. Semin Diagn Pathol. 28:245–255. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Kluin-Nelemans JC, Hoster E and Walewski
J: R-CHOP Versus R-FC followed by maintenance with rituximab versus
interferon-α: outcome of the first randomized Trial for elderly
patients with mantle cell lymphoma. Blood. 118:4932011.
|
|
64.
|
Sjöberg J, Halthur C, Kristinsson SY, et
al: Progress in Hodgkin lymphoma: a population-based study on
patients diagnosed in Sweden from 1973–2009. Blood. 119:990–996.
2012.PubMed/NCBI
|
|
65.
|
Kurtova AV, Tamayo AT, Ford RJ and Burger
JA: Mantle cell lymphoma cells express high levels of CXCR4, CXCR5,
and VLA-4 (CD49d): importance for interactions with the stromal
microenvironment and specific targeting. Blood. 113:4604–4613.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Mraz M, Zent CS, Church AK, et al: Bone
marrow stromal cells protect lymphoma B-cells from
rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4)
with natalizumab can overcome this resistance. Br J Haematol.
155:53–64. 2011.PubMed/NCBI
|
|
67.
|
Geissmann F, Ruskoné-Fourmestraux A,
Hermine O, et al: Homing receptor α4β7 integrin expression predicts
digestive tract involvement in mantle cell lymphoma. Am J Pathol.
153:1701–1705. 1998.
|
|
68.
|
Del Giudice I, Messina M, Chiaretti S, et
al: Behind the scenes of non-nodal MCL: downmodulation of genes
involved in actin cytoskeleton organization, cell projection, cell
adhesion, tumour invasion, TP53 pathway and mutate status of
immunoglobulin heavy chain genes. Br J Haematol. 156:601–611.
2012.
|
|
69.
|
Advani RH, Buggy JJ, Sharman JP, et al:
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has
significant activity in patients with relapsed/refractory B-cell
malignancies. J Clin Oncol. 31:88–94. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70.
|
Chang BY, Francesco M, De Rooij J, et al:
Egress of CD19+CD5+ cells into peripheral
blood following treatment with the BTK inhibitor ibrutinib in
mantle cell lymphoma patients. Blood. 122:2414–2422. 2013.
|
|
71.
|
Ferry JA: Burkitt’s lymphoma:
clinicopathologic features and differential diagnosis. Oncologist.
11:375–383. 2006.
|
|
72.
|
Gunn MD, Ngo VN, Ansel KM, Ekland EH,
Cyster JG and Williams LT: A B-cell-homing chemokine made in
lymphoid follicles activates Burkitt’s lymphoma receptor-1. Nature.
391:799–803. 1998.PubMed/NCBI
|
|
73.
|
Birkenbach M, Josefsen K, Yalamanchili R,
Lenoir G and Kieff E: Epstein-Barr virus-induced genes: first
lymphocyte-specific G protein-coupled peptide receptors. J Virol.
67:2209–2220. 1993.PubMed/NCBI
|
|
74.
|
Lalor S and Segal BM: Lymphoid chemokines
in the CNS. J Neuroimmunol. 224:56–61. 2010. View Article : Google Scholar
|
|
75.
|
Pranzatelli MR, Tata ED, McGee NR, et al:
Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell
recruitment in pediatric OMS. J Neuroimmunol. 243:81–88. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
76.
|
Rincon J, Prieto J and Patarroyo M:
Expression of integrins and other adhesion molecules in
Epstein-Barr virus-transformed B lymphoblastoid cells and Burkitt’s
lymphoma cells. Int J Cancer. 51:452–458. 1992.PubMed/NCBI
|
|
77.
|
Inghirami G, Grignani F, Sternas L,
Lombardi L, Knowles DM and Dalla-Favera R: Down-regulation of LFA-1
adhesion receptors by c-myc oncogenie in human B
lymphoblastoid cells. Science. 250:682–686. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Kadin M and Rathore B: Hodgkin’s lymphoma
therapy: past, present, and future. Exp Opin Pharmacother.
11:2891–2906. 2010.
|
|
79.
|
Steidl C, Connors JM and Gascoyne RD:
Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence
of the importance of the microenvironment. J Clin Oncol.
29:1812–1826. 2011.
|
|
80.
|
Maggio E, van den Berg A, Diepstra A,
Kluiver J, Visser L and Poppema S: Chemokines, cytokines and their
receptors in Hodgkin’s lymphoma cell lines and tissues. Ann Oncol.
13:52–56. 2002.
|
|
81.
|
Ellis PA, Hart DN, Colls BM, Nimmo JC,
MacDonald JE and Angus HB: Hodgkin’s cells express a novel pattern
of adhesion molecules. Clin Exp Immunol. 90:117–123. 1992.
|
